Lactobacillus fermentum CECT5716 for Respiratory Infections: Evidence Review
The user asks about the strength of evidence for Lactobacillus fermentum CECT5716 in reducing respiratory infections. The assistant explains that the evidence is moderately supportive, especially in infants, with multiple RCTs showing reduced incidence and duration. The evidence is weaker in adults, and the strain may work by modulating immune responses.
Does Lactobacillus fermentum CECT5716 actually help reduce respiratory infections, or is the evidence for it pretty weak?
Thank you for the question. Let me share what is known from the scientific literature about this specific probiotic strain.
Lactobacillus fermentum CECT5716 & Respiratory Infections
Lactobacillus fermentum CECT5716 (also known as LC40) is a probiotic strain originally isolated from human breast milk. It has been studied in several clinical contexts, particularly in maternal and infant health.
What the evidence shows
The evidence for Lactobacillus fermentum CECT5716 specifically helping reduce respiratory infections is moderately supportive, but not overwhelming.
- In infants: Several clinical trials have tested this strain (often in infant formula) and found statistically significant reductions in the incidence of respiratory tract infections, as well as shorter durations of episodes compared to placebo. For example, studies in healthy infants have reported fewer episodes of bronchitis, bronchiolitis, and other respiratory illnesses.
- In adults: There is less evidence specific to CECT5716 for respiratory infections in general adult populations. Most of the robust data focuses on the pediatric cohort.
- In breastfeeding mothers: Some research suggests that supplementing lactating mothers with CECT5716 can reduce the incidence of mastitis, which is an inflammatory/infectious condition, but not directly a respiratory endpoint.
How it's thought to work
The proposed mechanisms include modulation of the gut microbiota, enhancement of mucosal immune responses (e.g., increased secretory IgA), and stimulation of natural killer (NK) cell activity — all of which could theoretically help the body clear respiratory pathogens more effectively.
Verdict
- The evidence for CECT5716 reducing respiratory infections in infants and young children is reasonably solid, with multiple randomized controlled trials supporting the claim.
- The evidence in older children and adults is significantly thinner and less conclusive.
- Compared to other well-studied probiotics for respiratory health (like Lactobacillus rhamnosus GG or certain Bifidobacterium strains), CECT5716 has a narrower evidence base.
So, to answer your question directly: the evidence is not weak, but it is also not strong across all age groups. It's best characterized as promising for infants, with need for further research in other populations.